Literature DB >> 23195666

Role of microsatellite instability in the management of colorectal cancers.

Bruno Buecher1, Wulfran Cacheux, Etienne Rouleau, Barbara Dieumegard, Emmanuel Mitry, Astrid Lièvre.   

Abstract

Microsatellite instability is the consequence of a deficient mismatch repair system. It has a key role in the diagnostic strategy of Lynch syndrome, where tumours are all characterized by the presence of this phenotype. Microsatellite instability is therefore essential in the selection of colorectal cancer patients in whom a germline analysis of Mismatch Repair genes is possibly indicated. Moreover, microsatellite instability tumours are associated with a good prognosis and a resistance to fluorouracil-based adjuvant chemotherapy, which has a clinical application mainly in stage II colon cancer patients in whom adjuvant chemotherapy has a less beneficial effect than in stage III and outcome in presence of microsatellite instability is excellent. Recent data suggest that impact of microsatellite instability on benefit to fluorouracil-based adjuvant chemotherapy is dependent of the molecular mechanism involved in this genetic instability since an improved survival has been reported with adjuvant fluorouracil in microsatellite instability colorectal cancers of germline origin but not in sporadic cases. Predictive value of microsatellite instability on response to fluorouracil/oxaliplatin adjuvant chemotherapy has been less evaluated but recent studies suggest that the favorable outcome of Microsatellite instability tumours is maintained in patients receiving FOLFOX.
Copyright © 2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23195666     DOI: 10.1016/j.dld.2012.10.006

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  25 in total

1.  Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach.

Authors:  Charly Liddell; Laure Droy-Dupré; Sylvie Métairie; Fabrice Airaud; Christelle Volteau; Stéphane Bezieau; Christian L Laboisse; Jean-François Mosnier
Journal:  Mod Pathol       Date:  2017-04-21       Impact factor: 7.842

Review 2.  Phospholipid remodeling and eicosanoid signaling in colon cancer cells.

Authors:  Siddhartha Das; Leobarda Robles Martinez; Suparna Ray
Journal:  Indian J Biochem Biophys       Date:  2014-12       Impact factor: 1.918

3.  Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.

Authors:  Junli Ma; Yan Zhang; Hong Shen; Linda Kapesa; Wenqiang Liu; Mengsi Zeng; Shan Zeng
Journal:  Tumour Biol       Date:  2015-07-05

Review 4.  The molecular basis of rectal cancer.

Authors:  Michelle Shiller; Sarah Boostrom
Journal:  Clin Colon Rectal Surg       Date:  2015-03

5.  Evaluation of Long-Term Outcomes of Microsatellite Instability Status in an Asian Cohort of Sporadic Colorectal Cancers.

Authors:  Winson Jianhong Tan; Julie Liana Hamzah; Sanchalika Acharyya; Fung Joon Foo; Kiat Hon Lim; Iain Bee Huat Tan; Choong Leong Tang; Min Hoe Chew
Journal:  J Gastrointest Cancer       Date:  2018-09

6.  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

Authors:  Daniel D Buchanan; Yen Y Tan; Michael D Walsh; Mark Clendenning; Alexander M Metcalf; Kaltin Ferguson; Sven T Arnold; Bryony A Thompson; Felicity A Lose; Michael T Parsons; Rhiannon J Walters; Sally-Ann Pearson; Margaret Cummings; Martin K Oehler; Penelope B Blomfield; Michael A Quinn; Judy A Kirk; Colin J Stewart; Andreas Obermair; Joanne P Young; Penelope M Webb; Amanda B Spurdle
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

7.  Human mutL homolog 1 expression characteristic and prognostic effect on patients with sporadic colorectal cancer.

Authors:  Chibin Pu; Weiguo Ren; Zhenqiang Sun; Xianbo Yu; Wei Yuan; Mingyu Huang; Shourong Shen; Xiaoyan Wang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

8.  Age and Lymph Node Positivity in Patients With Colon and Rectal Cancer in the US Military Health System.

Authors:  Melannie S Alexander; Jie Lin; Craig D Shriver; Katherine A McGlynn; Kangmin Zhu
Journal:  Dis Colon Rectum       Date:  2020-03       Impact factor: 4.412

9.  Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.

Authors:  Dimitrios Pectasides; Vasilios Karavasilis; George Papaxoinis; Georgia Gourgioti; Thomas Makatsoris; Georgia Raptou; Eleni Vrettou; Joseph Sgouros; Epaminontas Samantas; George Basdanis; Pavlos Papakostas; Dimitrios Bafaloukos; Vassiliki Kotoula; Haralambos P Kalofonos; Chrisoula D Scopa; George Pentheroudakis; George Fountzilas
Journal:  BMC Cancer       Date:  2015-05-10       Impact factor: 4.430

Review 10.  The significance of markers in the diagnosis of endometrial cancer.

Authors:  Monika M Żyła; Jacek R Wilczyński; Marta Kostrzewa; Kinga Księżakowska-Łakoma; Marek Nowak; Grzegorz Stachowiak; Krzysztof Szyłło; Tomasz Stetkiewicz
Journal:  Prz Menopauzalny       Date:  2016-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.